No description available.

The KtrAB system of Vibrio alginolyticus is a sodium-dependent potassium transport system. KtrB, the membrane integral and K+ translocating subunit of the KtrAB complex, belongs to a superfamily of K+ transporter (SKT). These proteins are likely to have evolved from simple K+ channels of the M1PM2 type like KcsA by multiple gene duplication and gene fusion. They share a so called fourfold M1PM2-motif, in which two transmembrane helices (M1 and M2) are connected by a p-loop (P), which folds half back into the membrane. Comparing members of this superfamily with the K+ channel KcsA for structural predictions a striking amino acid sequence in helix M2C was found. In VaKtrB the first part of this helix, M2C1, consists of 12 hydrophobic amino acids and is expected to form an α-helix. The following very flexible and hydrophilic part, M2C2, with many glycines and small, partly polar amino acids is not supposed to have a helical conformation. By contrast, the last part, M2C3, shows a partial amphipathic and α-helical character, followed by three positive charged amino acids (R341, K343, K344) which are consistent with the "positive inside rule" and should be localized in the cytoplasm. Due to these findings Durell and Guy in 1999 hypothesised two possible folding models for segments PC and M2C but till now the conformation of this part remains unclear. In this thesis the role of the M2C region was studied in more detail. Point and partial to complete deletions in M2C2 led to a huge increase in Vmax for K+ transport while the affinity for potassium and the sodium transport properties were unaffected. Together with some PhoA-fusion studies which indicated that M2C2 forms a flexible structure within the membrane these data were interpreted to mean that M2C2 forms a flexible gate controlling K+ translocation at the cytoplasmic side of KtrB. This hypothesis was confimed by EPR measurements of single and double spin-labeled cysteine variants of KtrB. It was shown that M2C2 forms a loop inside the cavity of the protein. Upon the addition of K+ ions M2C2 residue T318R1 moved both with respect to M2B residue D222R1 and to M2C3 residue V331, but not with respect to M2C1 residue M311R1. Other residues within M2B, M2C1 and M2C3 did not move with respect to each other. With the help of a rotamer library analysis the measured distances were used to propose two new models for the structure of the M2C2 gate inside the KtrB protein in a closed conformation in the absence of K+ ion and in an open conformation in the presence of K+ ions. Since a flexible gate like M2C2 is missing in potassium channels, it is interpreted to be a transporter-specific structure. In the context of the analysis of the role of M2C2 in purified and reconstituted KtrB by biochemical and biophysical approaches a protocol for the overproduction, purification and reconstitution of natively folded, active protein was developed. In addition, results obtained from static light scattering measurements are shown in order to gain information about the oligomeric state of single subunits as well as of the assembled KtrAB complex.

No description available.

The oncogene Anaplastic Lymphoma Kinase (ALK) is a Receptor Tyrosine Kinase (RTK) and was initially discovered as the fusion protein NPM (nucleophosmin)-ALK in a subset of Anaplastic Large Cell Lymphomas (ALCL). Since then more fusion proteins have been identified in a variety of cancers. Further, overexpression of ALK due to gene amplification has been observed in many malignancies, amongst others neuroblastoma, a pediatric cancer. Lately, activating point mutations in the kinase domain of ALK have been described in neuroblastoma patients and neuroblastoma cell lines. In contrast, the physiological function of ALK is still unclear, but ALK is suggested to play a role in the normal development and function of the nervous system. By employing cell culture based approaches, including a tetracycline-inducible PC12 cell system and the in vivo D. melanogaster model system, we aimed to analyze the downstream signalling of ALK and its role in neuroblastoma. First, we wished to analyze whether ALK is able to activate the small GTPase Rap1 contributing to differentiation/proliferation processes. Activated ALK recruits a complex of the GEF C3G and CrkL and activates C3G by tyrosine phosphorylation. This activated complex is able to activate Rap1 resulting either in neurite outgrowth in PC12 cells or proliferation of neuroblastoma cells suggesting a potential role in the oncogenesis of neuroblastoma driven by gain-of-function mutant ALK. Next, we could show that seven investigated ALK mutations with a high probability of being oncogenic (G1128A, I1171N, F1174L, F1174S, R1192P, F1245C and R1275Q), are true gain-of-function mutations, respond differently to ALK inhibitors and have different transforming ability. Especially the F1174S mutation correlates with aggressive disease development. However, the assumed active germ line mutation I1250T is in fact a kinase dead mutation and suggested to act as a dominant-negative receptor. Finally, ALK mutations are most frequently observed in MYCN amplified tumours correlating with a poor clinical outcome. Active ALK regulates mainly the initiation of MYCN transcription in human neuroblastoma cell lines. Further, ALK gain-of-function mutants and MYCN synergize in transforming NIH3T3 cells. Overall, somatic mutations appear to be more aggressive than germ line mutations, implying a different impact on neuroblastoma. Further, successful application of ALK inhibitors suggests a promising future for the development of patient-specific treatments for neuroblastoma patients.

This work identified an ortholog of Abp1 (actin binding protein 1) in Dictyostelium (Dabp1). In order to analyze the functions of Dabp1 in Dictyostelium, loss-of–function studies and gain-of-function studies were performed by generating cells that either deleted the Dabp1 gene from the genome or overexpressed the Dabp1 protein. In these mutants, most actin-based processes were intact. However, cell motility was altered during early development. During chemotactic streaming, more than 90% of wild type cells had a single leading pseudopodium and a single uropod, whereas more than 27% of Dabp1 null cells projected multiple pseudopodia. Similarly, ~ 90% of cells that overexpressed Dabp1 projected multiple pseudopodia during chemotactic streaming, and displayed reduced rates of cell movement. Expression of the SH3 domain of Dabp1 showed this domain to be an important determinant in regulating pseudopodium number. These results suggest that Abp1 controls pseudopodium number and motility in early stages of chemotactic aggregation in Dictyostelium. This work also revealed an interplay between Dabp1 and MyoB, one of the Myosin I proteins, in controlling pseudopodia formation in Dictyostelium. These two proteins colocalize partially at the cortex in growing cells. The peripheral localization of MyoB was dependent on Dabp1. Depletion of both Dabp1 and MyoB caused defects in organization of the actin cytoskeleton and actin related activities such as formation of small F-actin filled spikes on the cell cortex of growing cells, a higher percentage of multinucleated cells, and an increased number of pseudopodia branching extensively. When MyoB was overexpressed in Dabp1 null mutants, cells had similar phenotypes as Dabp1/MyoB double null mutants, and displayed an increased number of pseudopodia with many branches. Overexpression of Dabp1 in MyoB null mutants rescued the defects in pseudopodia formation. The SH3 of Dabp1 was shown to be important for the rescue of defects caused by depletion of MyoB. Collectively, these data suggest that MyoB and Dabp1 work cooperatively to regulate the uniformity and integrity of the actin extensions during chemotaxis. MyoB requires Dabp1 to function in this process. Dabp1 may function as a scaffold to recruit MyoB to the proper localization. These studies of Dabp1 in Dictyostelium raise broad question about functions of actinassociated proteins in pseudopodia formation and the importance of uniformity and integrity for actin structures in chemotaxis. / text

Récemment, notre laboratoire a décrit plusieurs patients atteints d’une forme sévère et progressive de dystonie présentant des mutations de novo dans le gène du récepteur bêta de l’acide rétinoïque (RARB). RARB est un facteur de transcription activé lors de sa liaison à l’acide rétinoïque (AR), un élément essentiel au bon développement du cerveau. Des études de transfection indiquent que ces mutations augmentent l’activité transcriptionnelle de RARB, suggérant qu’elles confèrent un gain de fonction (GDF) à la protéine. La dystonie est typiquement expliquée par un dysfonctionnement du striatum, la structure où RARB est principalement exprimé. Chez la souris, la perte de fonction de Rarb entraîne une réduction des neurones striatonigraux et des anomalies motrices, suggérant une perturbation du développement des circuits striataux. Nous avons ainsi émis l’hypothèse selon laquelle la dystonie des patients porteurs de mutations de GDF serait causée par un accroissement de la signalisation de RARB, pouvant perturber l’homéostasie des mêmes circuits que ceux affectés par une diminution de la signalisation de Rarb. En utilisant la technologie CRISPR-Cas9, nous avons généré des souris portant la mutation p.R394C, homologue de la p.R387C retrouvée chez plusieurs patients. Ces souris RarbR394C/+ présentent des anomalies locomotrices rappelant celles d’autres modèles murins de dystonie, ainsi qu’une diminution des neurones striatopallidaux. Ceci suggère que les mutations de GDF de RARB induisent la dystonie en perturbant l’équilibre dans la signalisation dopaminergique striatale. Finalement, cette étude pourrait contribuer à comprendre les troubles neurodégénératifs moteurs, comme les maladies de Huntington et de Parkinson, dans lesquels la signalisation de l’AR semble être compromise. / We previously described several patients with a severe and progressive form of early-onset dystonia who carried de novo mutations in the retinoic acid receptor beta gene (RARB). RARB is a transcription factor that is activated upon binding to retinoic acid (RA), whose signaling is required for proper development of the brain. Transfection studies indicate that these de novo mutations increase RARB transcriptional activity, suggesting that they confer a gain-of-function (GOF) propriety to the protein. Dystonia is typically explained by some dysfunction of the striatum, a region where RARB is predominantly expressed. Interestingly, loss of Rarb function in mice leads to a reduction of striatonigral neurons and motor abnormalities, suggesting a disruption in early development of striatal circuits. We hypothesized that the motor impairment of patients with RARB GOF mutations is caused by increased RARB signaling in the striatum, possibly disrupting homeostatic control of the same pathways as those affected by decreased Rarb signaling. Using CRISPR-Cas9 technology, we generated mice carrying the mutation p.R394C, which is homologous to the GOF mutation p.R387C found in several patients. These RarbR394C/+ mice show locomotor impairments reminiscent of that of other mouse models of dystonia, along with a decreased striatopallidal neuronal population. Our data suggest that GOF mutations in RARB induce dystonia by disrupting striatal dopaminergic signaling necessary for functional equilibrium. This work might also shed light on common neurodegenerative disorders of the basal ganglia including Huntington’s and Parkinson’s disease, in which RA and RARB signaling appear to be compromised.

No description available.

<p>Plant height is an important agronomic trait and a major target for crop improvement. Owing to the ease of detection and measurement of plant stature, as well as its high heritability, several height-related mutants have been reported in maize. The genes underlying a few of those mutants have also been identified, with a majority of them related to the biosynthesis or signaling of two key phytohormones - gibberellins (GAs) and brassinosteroids (BRs). However, most other maize dwarfing mutants, and especially those that result from gain-of-function mutations, remain uncharacterized. The present study was undertaken to characterize a novel dominant dwarfing mutant, named <i>D13</i>. This mutant appeared in the M1 population of the inbred B73 that was generated by mutagenesis with ethyl methanesulfonate (EMS). Like most other maize dwarfing mutants, the reduction in <i>D13</i> height was largely due to the compression of the internodes. However, unlike the GA or BR mutants, <i>D13</i> had no defects in the female or male inflorescences. Further, in contrast to the GA and BR mutants, the mesocotyl elongation during etiolation was not impacted in <i>D13</i>. <i>D13</i> seedlings developed red coloration in two to three lowermost leaves. In addition, <i>D13</i> also showed enhanced tillering when the phenotype was very severe. The size of the shoot apical meristem of <i>D13</i> was reduced slightly, and significant aberrations in the structure of vascular bundles in the mutant were observed. All anatomical and phenotypic features of <i>D13</i> were highly exaggerated in homozygous state, indicating the partially dominant nature of the <i>D13</i> mutation. Interestingly, the heterozygous mutants showed remarkable variation in their phenotype, which was maintained across generations. Moreover, the <i>D13</i> phenotype was found to be sensitive to the genetic background, being completely suppressed in Mo17, Oh7B, enhanced in CML322, P39 and changed to different degrees in others. To identify the genetic defect responsible for the <i>D13</i> mutant phenotype, a map-based cloning approach was used, which identified a single base-pair change from G to A (G2976A) in the coding region of a glutamate receptor gene (Zm00001d015007). The G2976A missense mutation resulted in the replacement of alanine with threonine at the location 670. The replaced alanine is highly conserved in glutamate receptors across all domains of life from cyanobacteria to plants to mammals, suggesting a causal relationship between the G2976A substitution and the <i>D13</i> phenotype. To validate this relationship, a targeted EMS-based mutagenesis approach was used to knock-out (inactivate) the <i>D13</i> mutant allele. A suppressor mutant was found in which the <i>D13</i> mutant phenotype reverted to the normal tall phenotype. The sequence of the revertant allele, designated <i>D13</i>*, revealed that the original <i>D13</i> mutant allele underwent a second G to A mutation (G1520A) to change glycine into aspartic acid at position 473. This intragenic second-site mutation in the <i>D13</i> allele suppressed the function of the <i>D13</i> allele, thereby preventing it from interfering with the function of the wild type allele. To further unveil the genes and underlying mechanisms that enable the <i>D13</i> mutant to confer a dwarf phenotype, transcriptomic and metabolomic analyses of <i>D13</i> mutants were conducted and compared to the wild type sibs. While the omics analysis confirmed that stress responses were upregulated and genes related to shoot system development were downregulated in the mutant, the data did not allow us to pinpoint the underlying mechanisms that connect the <i>D13</i> mutation with its dwarfing phenotype. Furthermore, it remains unclear whether these stress and shoot system-related changes result in the manifestation of <i>D13</i> phenotype, or the dwarf phenotype due to <i>D13</i> mutation activates the stress-related mechanisms. This is the first study that signifies the importance of a glutamate receptor gene in controlling plant height.</p>

Le syndrome d'Evans est défini par l'existence concomitante ou séquentielle de cytopénies auto-immunes, le plus souvent, anémie hémolytique et thrombopénie immunologique. Chez l'enfant, il peut être secondaire à une infection, une maladie auto-immune systémique ou un déficit immunitaire primitif. Alternativement, chez une grande partie des patients, l'étiologie n'est pas clairement identifiée. Les patients atteints de syndrome d'Evans présentent parfois d'autres atteintes, telles une auto-immunité d'organe, une lymphoprolifération bénigne ou un déficit immunitaire. L'objectif de ce travail était d'identifier des causes génétiques chez des enfants présentant un syndrome d'Evans sans étiologie sous-jacente identifiée. Nous avons centré notre étude sur des formes sévères à début pédiatrique en faisant l'hypothèse qu'une maladie monogénique serait plus fréquente dans ce groupe de patients. Nous avons mis à profit les technologies de séquençage haut débit « nouvelle génération » (NGS) pour réaliser et analyser le séquençage de l'exome de patients et de certains de leurs apparentés afin de mettre en évidence des gènes candidats potentiels. Ce travail a permis l'identification de 4 gènes candidats : LRBA, CTLA-4, STAT3 (mutations gain de fonction) et NFKBIA. L'implication des 3 premiers gènes dans de nouvelles maladies monogéniques où l'auto-immunité est au premier plan a été confirmée par d'autres équipes au cours de ce travail. Pour chacun de ces gènes, nous avons poursuivi 2 objectifs complémentaires : d'une part, tenter de valider l'implication des gènes identifiés dans la maladie des patients. Nous avons pour cela utilisé des approches et techniques variées : biochimie et protéomique afin d'identifier des partenaires protéiques, microscopie confocale pour localiser les protéines et leurs interactions, tests cellulaires in vitro pour mettre en évidence un défaut fonctionnel, marquages en cytométrie en flux pour identifier des modifications dans les sous-populations lymphocytaires. D'autre part, nous avons recherché d'autres mutations de ces gènes chez des patients de phénotype clinique similaire. Nous avons ainsi constitué et exploré 3 cohortes de patients présentant des mutations de LRBA, CTLA-4 ou STAT3. Nous avons rassemblé une cohorte de 18 patients porteurs d'une mutation de LRBA, répartis dans 11 familles. Cela nous a permis de préciser et d'étendre le spectre clinique de cette maladie de découverte récente, avec en particulier des atteintes articulaires sévères s'associant à un diabète précoce, ou des entéropathies. Nous avons identifié 15 nouvelles mutations de transmission autosomique récessive dans le gène LRBA, codant une protéine de fonction inconnue dont l'absence entraine une maladie principalement caractérisée par une poly-auto-immunité. Nous avons identifié 29 partenaires protéiques potentiels de LRBA et précisé la localisation de LRBA dans les différents compartiments cellulaires. Nous avons également établi une cohorte de 12 patients dans 10 familles présentant un déficit en CTLA-4 par haplo-insuffisance. Au delà de la mise en évidence de 9 nouvelles mutations, nous avons décrit une famille où la variation est transmise de façon autosomique récessive. Dans les déficits en LRBA et CTLA-4, nous avons mis en évidence une diminution du pourcentage de lymphocytes T régulateurs parmi les PBMC et une diminution de l'expression de CTLA-4 dans les lymphocytes T activés. Ceci corrobore l'interaction entre ces 2 protéines décrite en parallèle par une autre équipe. Nous avons montré que les spectres cliniques des déficits en LRBA et CTLA-4, fortement chevauchant dans les premières descriptions publiées, pourraient se différencier, malgré l'implication des lymphocytes T régulateurs dans ces 2 maladies. (...) / Evans syndrome is defined by the occurence of autoimmune cytopenias, either at the same time or sequential, mainly autoimmune hemolytic anemia and immune thrombocytopenia. In children, it may be secondary to infections, systemic autoimmune disease, or primary immune deficiency, though in most patients, its etiology isn't obvious. Patients affected with Evans syndrome can also present other features, such as autoimmunity toward a particular organ, benign lymphoproliferation or immunodeficiency. The main goal of this work was to identify genetic causes in children presenting an Evans syndrome without a known underlying etiology. We focused our study on severe, early onset forms of the disease, with the hypothesis that a monogenic disease would be more frequent in this group of patients. Taking advantage of high throughput "Next Generation" sequencing (NGS) techniques, we sequenced and analyzed exome from patients and their relatives in search for adequate candidate genes. We identified 4 candidate genes: LRBA, CTLA-4, STAT3 (gain-of-function mutations), and NFKBA. Implication of the first 3 genes in new monogenic diseases with autoimmunity as a key feature was also confirmed by others during the course of this work. For each gene, we pursued 2 complementary goals: First, we sought to validate the implication of the gene in the patients' disease. To do so, we used various techniques and approaches: biochemistry and proteomics to identify protein partners, confocal microscopy to localize proteins and interactions, in vitro cellular assays to bring to light functional defect, flow cytometry to identify changes in lymphocytes subpopulations. We also looked for other mutations of each gene in patients with a similar clinical presentation. Hence we created and explored 3 cohorts of patients presenting with mutations of LRBA, CTLA-4 or STAT3. We constituted a cohort of 18 patients with LRBA mutations within 11 families. We then were able to precise and extend the clinical spectrum of this recently described disease. In particular, we observed patients with severe chronic arthritis associated with diabetes mellitus or enteropathies. We identified 15 new mutations of autosomal recessive transmission in the LRBA gene, coding a protein of unknown function, which absence is responsible for a disease mainly characterized by autoimmune features. We identified 29 candidate protein partners of LRBA and precized LRBA localisation in cell compartiments. We also established a cohort of 12 patients within 10 families presenting CTLA-4 haploinsufficiency. Beyond describing 9 new mutations, we report a family with autosomal recessive transmission.In LRBA and CTLA-4 deficiencies, we showed a decrease of regulatory T lymphocyte subset proportion among PBMC and a decrease of CTLA-4 expression in activated T cells. These results support the interaction between these 2 proteins, described concurrently by another team. We showed that the clinical spectra of these 2 diseases, although widely overlapping in first published reports, could be different despite a role of regulatory T cells in both. Hence, organ-specific autoimmunity and lymphoproliferation are more frequent in LRBA deficiency whereas granuloma and hypogammaglobulinemia are more present in CTLA-4 deficiency. Theses results suggests a role of genetic modifyers, which remain to identify. Among our cohort of patients with Evans syndrome, we also identified 5 patients within 5 families presenting gain-of-function mutations of STAT3. 3 of those mutations were reported by others during our work and appeared de novo in our patients. Functional validation of the 4th one is in progress. The last mutation follows a recessive transmission and could exemplify a new transmission modality of this disease. (...)

Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) is the ninth member of the Ca+2-dependent mammalian proprotein convertase super family of serine endoproteases that is structurally related to the bacterial subtilisin and yeast kexin enzymes. It plays a critical role in the regulation of lipid metabolism and cholesterol homeostasis by binding to and degrading low-density lipoprotein-receptor (LDL-R) which is responsible for the clearance of circulatory LDL-cholesterol from the blood. Owing to this functional property, there is plenty of research interest in the development of functional inhibitors of PCSK9 which may find important biochemical applications as therapeutic agents for lowering plasma LDL-cholesterol. The catalytic domain of PCSK9 binds to the EGF-A domain of LDL-R on the cell surface to form a stable complex and re-routes the receptor from its normal endosomal recycling pathway to the lysosomal compartments leading to its degradation. Owing to these findings, we propose that selected peptides from PCSK9 catalytic domain, particularly its disulphide (S-S) bridged loop1 323-358 and loop2 365-385, are likely to exhibit strong affinity towards the EGF-A domain of LDL-R. Several regular peptides along with corresponding all- dextro and retro-inverse peptides as well as the gain-of-function mutant variants were designed and tested for their regulatory effects towards LDL-R expression and PCSK9-binding in human hepatic HepG2 and mouse hepatic Hepa1c1c7 cells. Our data indicated that disulfide bridged loop1-hPCSK9323-358 and its H357 mutant as well as two short loop2-hPCSK9372-380 and its Y374 mutant peptides modestly promote the LDL-R protein levels. Our study concludes that specific peptides from the PCSK9 catalytic domain can regulate LDL-R and may be useful for development of novel class of therapeutic agents for cholesterol regulation.